S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Genfit Stock Forecast, Price & News

+0.02 (+0.65%)
(As of 07/4/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
80,987 shs
Average Volume
Market Capitalization
P/E Ratio
Dividend Yield
Price Target

Genfit MarketRank™ Forecast

Analyst Rating
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.22 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Genfit logo

About Genfit (EPA:GNFT) Stock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

GNFT Stock News Headlines

GNFT Genfit S.A.
Genfit reports Q1 results
Genfit GAAP EPS of €1.23, revenue of €85.58M
GENFIT S.A. American Depositary Shares (GNFT)
Why Genfit Shares Are Rising
Pre-market Movers: GNFT, ABEO, SPRB, IO, CERN…
GENFIT: Publication of the 2020 Universal...
GENFIT: 2021 Financial Calendar
See More Headlines

Industry, Sector and Symbol

Year Founded


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Not Optionable

Genfit Frequently Asked Questions

How has Genfit's stock performed in 2022?

Genfit's stock was trading at €4.32 on January 1st, 2022. Since then, GNFT shares have decreased by 28.2% and is now trading at €3.10.
View the best growth stocks for 2022 here

Who are Genfit's key executives?

Genfit's management team includes the following people:
  • Mr. Jean-Francois Mouney, Co-Founder & Chairman (Age 67, Pay $332.42k)
  • Mr. M. Pascal Prigent, Chief Exec. Officer (Age 54, Pay $503.74k)
  • Prof. Bart Staels, Co-Founder & Chairman of the Scientific Advisory Board (Age 59)
  • Mr. Thomas Baetz, Chief Financial Officer (Age 48)
  • Mr. Pascal Caisey, Chief Operating Officer (Age 54)
  • Dr. Dean W. Hum Ph.D., Chief Scientific Officer (Age 60)
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 52)
  • Ms. Stefanie Magner, Chief Compliance Officer & VP of International Legal Affairs (Age 41)
  • Ms. Emilie Desodt, Vice-Pres of HR (Age 39)
  • Mr. Jean-Christophe Marcoux, Chief Strategy Officer (Age 45)

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Algonquin Power & Utilities (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT).

What is Genfit's stock symbol?

Genfit trades on the EPA under the ticker symbol "GNFT."

What is Genfit's stock price today?

One share of GNFT stock can currently be purchased for approximately €3.10.

How many employees does Genfit have?

Genfit employs 122 workers across the globe.

How can I contact Genfit?

Genfit's mailing address is Parc Eurasante 885 avenue Eugene Avinee, Loos, Hauts De France 59120. The official website for Genfit is www.genfit.com. The company can be reached via phone at 33 3 20 16 40 00.

This page (EPA:GNFT) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.